ATE351906T1 - Zur modulation der krebszellenproliferation geeignetes polynukleotid - Google Patents

Zur modulation der krebszellenproliferation geeignetes polynukleotid

Info

Publication number
ATE351906T1
ATE351906T1 AT02748337T AT02748337T ATE351906T1 AT E351906 T1 ATE351906 T1 AT E351906T1 AT 02748337 T AT02748337 T AT 02748337T AT 02748337 T AT02748337 T AT 02748337T AT E351906 T1 ATE351906 T1 AT E351906T1
Authority
AT
Austria
Prior art keywords
cell proliferation
cancer cell
modulating cancer
polynucleotide suitable
modulating
Prior art date
Application number
AT02748337T
Other languages
English (en)
Inventor
Eric Ferrandis
Y Ferrer Jose-Antonio Camara
Jean Martinez
Christophe Thurieau
Original Assignee
Sod Conseils Rech Applic
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic, Centre Nat Rech Scient filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of ATE351906T1 publication Critical patent/ATE351906T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02748337T 2001-03-01 2002-03-01 Zur modulation der krebszellenproliferation geeignetes polynukleotid ATE351906T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0102801A FR2821624B1 (fr) 2001-03-01 2001-03-01 Nouveau polynucleotide utilisable pour moduler la proliferation des cellules cancereuses

Publications (1)

Publication Number Publication Date
ATE351906T1 true ATE351906T1 (de) 2007-02-15

Family

ID=8860611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02748337T ATE351906T1 (de) 2001-03-01 2002-03-01 Zur modulation der krebszellenproliferation geeignetes polynukleotid

Country Status (20)

Country Link
US (1) US7214533B2 (de)
EP (1) EP1368474B1 (de)
JP (1) JP4190291B2 (de)
KR (1) KR100869190B1 (de)
CN (1) CN1289670C (de)
AT (1) ATE351906T1 (de)
AU (1) AU2002335492B2 (de)
BR (1) BR0207253A (de)
CA (1) CA2437535C (de)
CZ (1) CZ20032670A3 (de)
DE (1) DE60217651T2 (de)
ES (1) ES2279877T3 (de)
FR (1) FR2821624B1 (de)
HU (1) HUP0303312A3 (de)
IL (1) IL157091A0 (de)
MX (1) MXPA03007694A (de)
NZ (1) NZ527261A (de)
PL (1) PL204844B1 (de)
RU (1) RU2307666C2 (de)
WO (1) WO2002070700A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
KR20230145206A (ko) * 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
KR102427379B1 (ko) * 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637456A (en) * 1995-02-17 1997-06-10 The University Of Texas, Board Of Regents Rapid test for determining the amount of functionally inactive gene in a gene therapy vector preparation
WO2000069454A1 (en) * 1999-05-17 2000-11-23 Board Of Regents, The University Of Texas System Suppression of endogenous igfbp-2 to inhibit cancer

Also Published As

Publication number Publication date
EP1368474A1 (de) 2003-12-10
CN1494591A (zh) 2004-05-05
US7214533B2 (en) 2007-05-08
JP4190291B2 (ja) 2008-12-03
CA2437535C (fr) 2011-05-10
CN1289670C (zh) 2006-12-13
DE60217651T2 (de) 2007-10-18
DE60217651D1 (de) 2007-03-08
BR0207253A (pt) 2004-02-10
HUP0303312A2 (hu) 2003-12-29
FR2821624B1 (fr) 2004-01-02
KR100869190B1 (ko) 2008-11-18
US20040197783A1 (en) 2004-10-07
AU2002335492B2 (en) 2006-11-02
CZ20032670A3 (cs) 2004-04-14
MXPA03007694A (es) 2004-03-16
HK1065334A1 (en) 2005-02-18
EP1368474B1 (de) 2007-01-17
RU2307666C2 (ru) 2007-10-10
HUP0303312A3 (en) 2012-09-28
RU2003129163A (ru) 2005-02-20
FR2821624A1 (fr) 2002-09-06
IL157091A0 (en) 2004-02-08
ES2279877T3 (es) 2007-09-01
NZ527261A (en) 2005-06-24
JP2004527240A (ja) 2004-09-09
PL365226A1 (en) 2004-12-27
WO2002070700A1 (fr) 2002-09-12
PL204844B1 (pl) 2010-02-26
CA2437535A1 (fr) 2002-09-12
KR20030090655A (ko) 2003-11-28

Similar Documents

Publication Publication Date Title
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
DE69833670D1 (de) Homologe des tie-rezeptortyrosinekinase liganden
ATE437652T1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
IL150168A0 (en) Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods bsed thereon
DE69737814D1 (de) Gekürzte lösliche typ-i-rezeptoren für tumor-nekrose-faktor
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
DE69838249D1 (de) Anti-apo-2 antikörper
EA200600591A1 (ru) МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
PL414997A1 (pl) Zastosowanie 40-O-(2-hydroksyetylo)-rapamycyny do leczenia guzów litych nerki
ATE446314T1 (de) Methode zur reinigung von fsh
DE60207759D1 (de) Pyrimidotriazine als phosphataseinhibitoren
DE60237777D1 (de) Etzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie
DE60217651D1 (de) Zur modulation der krebszellenproliferation geeignetes polynukleotid
WO2002077263A3 (en) Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
ATE337296T1 (de) Verbindungen für die modulation der proliferation von zellen
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
DE60031856D1 (de) Säugeradhäsionprotease
GB0016362D0 (en) Tetraspanin modulation
AU2003222426A1 (en) Methods and compositions for modulating beta-catenin phosphorylation
ATE219515T1 (de) Methoden und reagenzien zur regulierung von apoptosis
DE69933690D1 (de) Apoptosis induzierender faktor
DE69739223D1 (de) Oden und anwendungen
AU2002251873A1 (en) Methods and compositions for modulating gluconeogenesis using pgc-1
IL164560A0 (de)
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties